Ignite Creation Date:
2025-12-25 @ 12:41 AM
Ignite Modification Date:
2026-02-27 @ 11:19 AM
Study NCT ID:
NCT02543567
Status:
COMPLETED
Last Update Posted:
2025-05-25
First Post:
2015-09-04
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants
Sponsor:
Janssen Vaccines & Prevention B.V.
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Healthy | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Ebola viruses | View |
| None | Ebola virus disease (EVD) | View |
| None | Filoviruses | View |
| None | Monovalent vaccine | View |
| None | Safety | View |
| None | Immunogenicity | View |
| None | Ebola vaccine | View |
| None | Human adenovirus serotype 26 (Ad26) expressing the Ebola virus Mayinga … | View |
| None | Modified Vaccinia Virus Ankara - Bavarian Nordic Filo-vector (MVA-BN Filo) | View |
| None | Healthy participants | View |